Physician

Christopher Michael Tully

According to 2025 Medicare claims, Christopher Tully (NPI: 1053585232) practices hematology/oncology in the Newark, NJ market, with the plurality of this provider's patient population coming from Morris, NJ. This provider's primary affiliated billing organization is ONCOLOGY & HEMATOLOGY SPECIALISTS,P.A. (NPI: 1962511147; TIN: 222132567) and primary practice location at 07046-1601.

Tully's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 462 traditional Medicare patients, billed 135,982 HCPCS/CPT codes, and received $3,853,757 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 295 prescription claims across 83 beneficiaries totaling $483,981 in drug costs, led by Procrit (Epoetin Alfa). 2021 DME data shows 24 claims. Open Payments data shows 117 records totaling $1,993. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $851,781 to $3,853,757. In contrast, Part D prescription costs have fallen sharply in recent years, from $1,189,355 to $483,981. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	527	89,769	$851,781
2016	616	129,553	$1,604,871
2017	576	182,819	$2,305,719
2018	562	140,790	$2,345,656
2019	520	160,434	$2,167,264
2020	443	233,326	$3,249,916
2021	470	215,692	$3,778,583
2022	412	137,038	$3,815,665
2023	400	114,288	$3,657,316
2024	462	135,982	$3,853,757

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	71	435	$1,189,355
2016	88	469	$1,189,073
2017	110	591	$1,744,949
2018	119	587	$1,344,282
2019	107	393	$757,085
2020	95	329	$723,511
2021	98	361	$287,224
2022	97	353	$762,386
2023	94	335	$263,616
2024	83	295	$483,981

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	46	$33,087
2016	N/R	43	$23,098
2017	N/R	82	$18,765
2018	N/R	N/R	N/R
2019	N/R	22	$2,537
2020	N/R	N/R	N/R
2021	N/R	24	$1,489
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	132	132	$198
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	373	1,477	$115
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	83	153	$60
36415	Insertion of needle into vein for collection of blood sample	344	1,443	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	338	1,401	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Procrit	Epoetin Alfa	13	364	$31,145
Eliquis	Apixaban	24	1,500	$27,613
Xarelto	Rivaroxaban	22	960	$17,777
Anastrozole	Anastrozole	43	2,550	$1,128
Hydroxyurea	Hydroxyurea	16	1,063	$149

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	117	$1,993	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Christopher Michael Tully?

Tedicare shows public-source Medicare data for Christopher Michael Tully (NPI 1053585232), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Christopher Michael Tully have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Christopher Michael Tully?

Christopher Michael Tully is linked to ONCOLOGY & HEMATOLOGY SPECIALISTS,P.A. (billing NPI 1962511147) in the available physician profile data.

Does Christopher Michael Tully have Open Payments data?

Christopher Michael Tully has 117 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.